236 Research news
Experimental Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer, May Be New Standard of Care

Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.

Exercise Eases Memory Problems in Women Treated for Breast Cancer

Women treated for breast cancer who did more moderate-to-vigorous exercise reported fewer memory problems.

Triple-Negative Breast Cancer's Response to Carboplatin Before Surgery Seems Affected By BRCA1/2 Mutation Status

In the GeparSixto study, women with a BRCA1 or BRCA2 mutation responded better to chemotherapy before surgery without carboplatin, while women without a mutation had better outcomes when carboplatin was added to the chemotherapy regimen.

Jul 14, 2017 | Diagnosis and Chemotherapy
Chemo and Radiation at the Same Time Improve Prognosis for Early-Stage Disease

Research suggests that treatment with chemotherapy and radiation at the same time can help keep breast cancer from coming back.

Taxotere Combo Improves Survival

The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.

Dec 13, 2007 | Diagnosis and Chemotherapy
If Cancer Stops Responding to Herceptin, It May Have Switched From HER2-Positive to HER2-Negative

A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.

New Chemo Meds Improve Survival for Women With Advanced-Stage Disease

Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.

Avastin Slows Growth of Metastatic Breast Cancer

Women diagnosed with metastatic breast cancer who got Avastin in combination with chemotherapy lived 1 to 3 months longer without the cancer growing compared to women who only got chemotherapy, but overall survival was the same for both groups.

New Medicines That Slow Cancer's Growth Don't Seem to Improve Survival

Research shows no link between progression-free survival and overall survival in experimental breast cancer treatment trials.

Chemo Brain Could Be Hormonal Therapy Brain

A small study suggests that hormonal therapy medicines may contribute to chemo brain more than chemotherapy does.

Zoladex May Help Preserve Fertility in Women Diagnosed With Early-Stage, Hormone-Receptor-Negative Disease Treated With Chemotherapy

A study suggests that women diagnosed with hormone-receptor-negative, early-stage breast cancer who were treated with Zoladex in addition to chemotherapy before surgery were much less likely to be infertile after chemotherapy ended.

Chemotherapy Before Surgery Can Reduce Recurrence Risk in Black Women

A study suggests that treating even early-stage breast cancer in Black women with chemotherapy before surgery can help reduce their risk of recurrence.

Adding Perjeta to Herceptin and Chemotherapy After Surgery Shows Benefits in Early-Stage HER2-Positive Breast Cancer

Updated results show adding Perjeta to Herceptin and chemotherapy after surgery for early-stage HER2-positive breast cancer continues to reduce the risk of recurrence and to slightly improve survival.

Chemotherapy-Linked Neuropathy Can Affect Balance, Gait Even Years After Treatment Ends

Neuropathy caused by chemotherapy increases the risk of falling.

Jun 15, 2017 | Diagnosis, Chemotherapy and Side Effects
Is Breast Cancer Linked to Higher Risk of Atrial Fibrillation?

Women diagnosed with breast cancer may have a higher risk of a type of heart problem called atrial fibrillation, according to a retrospective Danish study.

ASCO Updates Guidelines on Using Biomarkers to Make Adjuvant Treatment Decisions for Women Diagnosed With Early-Stage Invasive Breast Cancer

ASCO updates guidelines on using biomarkers to make decisions about systemic therapies after surgery to treat people diagnosed with early-stage invasive breast cancer to include recent results from the TAILORx trial on using the Oncotype DX test to guide use of chemotherapy after surgery.

Adding Tukysa to Standard Treatment Reduces Brain Lesion Growth Risk in HER2-Positive Metastatic Breast Cancer

For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow.

Oncotype DX May Help Make Treatment Decisions for Breast Cancer That's Metastatic at Diagnosis

A study suggests that the Oncotype DX test can offer relevant information about cancer progression and 2-year survival rates for women diagnosed with de novo stage IV cancer.

MammaPrint Test Can Help Estimate Risk of Recurrence

A study suggests the MammaPrint test can help estimate the risk of recurrence after surgery for early-stage disease.

Anthracycline Chemo Regimen Seems Better Than Regimen Without Anthracycline for Early-Stage, HER2-Negative, High-Risk Disease

Early results suggest that an anthracycline chemotherapy regimen is better than a regimen without an anthracycline for early-stage, HER2-negative disease with a high risk of recurrence.

Jun 20, 2016 | Diagnosis and Chemotherapy
Freezing Embryos Helps Women Conceive After Breast Cancer Treatment

Freezing embryos created from eggs extracted before treatment allowed women diagnosed with early-stage breast cancer to become pregnant at rates similar to women not diagnosed with breast cancer who underwent in vitro fertilization.

Older Women Do Better on Conventional Chemo Compared to Xeloda

Research shows that women older than 65 do better on standard intravenous chemotherapy after surgery to remove early-stage breast cancer than Xeloda (chemical name: capecitabine), an oral chemotherapy.

May 13, 2009 | Diagnosis and Chemotherapy
Measuring Circulating Tumor Cells May Help Determine Recurrence Risk

A test that measures circulating tumor cells in the blood may help doctors more accurately determine the risk of breast cancer recurrence.

Chemotherapy for Breast Cancer Doesn't Seem To Increase Risk of COVID-19 Infection or Death

Women treated with chemotherapy for breast cancer were no more likely to be infected with COVID-19 or die from COVID-19 than women treated with other medicines that don’t weaken the immune system.

Jul 7, 2021 | Chemotherapy
Showing 24 of 236